The development of HGSC screening assays based on genetic mutations is therefore challenging since TP53 is often the only driver gene mutated and would be quite non-specific given that TP53 is the most commonly mutated gene across all cancer types [188] and is also known to be present in benign ovarian tissue, compromising its performance as a screening biomarker [189,190]. The gene discussed is TP53; the disease is cancer.